ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Oftentimes, in BCR:ABL1-independent TKI-resistant CML, the RAF/MEK/ERK pathway will be activated through the increased expression of PKCη, whose subsequent phosphorylation of CRAF leads to increased proliferation and cell survival[60].